BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Inotek Pharmaceuticals Corporation 

100 Cummings Center, Suite 419E

Beverly  Massachusetts  01915  U.S.A.
Phone: 978-232-9660 Fax: 978-232-8975


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Pharmaceutical






 Company News
Inotek Pharmaceuticals Corporation Initiates Phase 2 Study With Trabodenoson In Combination With Latanoprost For Patients With Glaucoma Or Ocular Hypertension 3/10/2014 8:37:15 AM    More...
Inotek Pharmaceuticals Corporation Collects $21 Million for Development of Glaucoma Drug 9/27/2013 6:49:14 AM    More...
Inotek Pharmaceuticals Corporation Presents Positive Phase 2 Data of Trabodenoson in Glaucoma 11/8/2012 10:06:05 AM    More...
Inotek Pharmaceuticals Corporation to Present Phase 2 Data of Trabodenoson in Glaucoma at the Ophthalmology Innovation Summit 11/2/2012 8:34:08 AM    More...
Inotek Pharmaceuticals Corporation to Expand Phase 2 Clinical Trial in Glaucoma Based on Promising Preliminary Results 7/21/2011 10:25:48 AM    More...
Inotek Pharmaceuticals Corporation Initiates Multiple-Dose Phase 2 Clinical Trial of INO-8875 in Patients With Glaucoma 6/17/2010 9:40:28 AM    More...
Inotek Pharmaceuticals Corporation Brings In $18M For Eye Treatments 6/11/2010 8:30:19 AM    More...
Inotek Pharmaceuticals Corporation Presents Preclinical Data at ARVO Confirming That INO-8875 Lowers IOP by Increasing Outflow Through the Trabecular Meshwork 5/4/2010 11:54:54 AM    More...
Inotek Pharmaceuticals Corporation to Present New Preclinical Data on Novel Mechanism of Action for Lead Glaucoma Candidate INO-8875 4/27/2010 10:55:36 AM    More...
Inotek Pharmaceuticals Corporation to Present at the Cowen and Company 30th Annual Health Care Conference on Thursday, March 11 3/4/2010 10:51:37 AM    More...
12345